A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC

BACKGROUND: Endostar is a strong angiogenesis inhibitor that is effective in treating non-small cell lung cancer (NSCLC), but the effect of Endostar in the treatment of patients with EGFR-TKI-resistant NSCLC remains unclear. We evaluated the clinical efficacy and safety of Endostar in EGFR-mutant NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Bing, Kang, Yanrong, Wang, Haiji, Wang, Jian, Shen, Rong, Liu, Shuai, Lu, Lu, Sun, Zhigang, Zhang, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638772/
https://www.ncbi.nlm.nih.gov/pubmed/37951898
http://dx.doi.org/10.1186/s12890-023-02705-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638772/
https://www.ncbi.nlm.nih.gov/pubmed/37951898
http://dx.doi.org/10.1186/s12890-023-02705-z

Ejemplares similares